GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OCSE:NSIS B) » Definitions » Capex-to-Operating-Cash-Flow

Novonesis (Novozymes) B (OCSE:NSIS B) Capex-to-Operating-Cash-Flow : 0.52 (As of Mar. 2025)


View and export this data going back to 2000. Start your Free Trial

What is Novonesis (Novozymes) B Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Novonesis (Novozymes) B's Capital Expenditure for the three months ended in Mar. 2025 was kr-411.72 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2025 was kr793.61 Mil.

Hence, Novonesis (Novozymes) B's Capex-to-Operating-Cash-Flow for the three months ended in Mar. 2025 was 0.52.


Novonesis (Novozymes) B Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Novonesis (Novozymes) B's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Capex-to-Operating-Cash-Flow Chart

Novonesis (Novozymes) B Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.31 0.72 0.50 0.35

Novonesis (Novozymes) B Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.29 0.28 0.43 0.52

Competitive Comparison of Novonesis (Novozymes) B's Capex-to-Operating-Cash-Flow

For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novonesis (Novozymes) B's Capex-to-Operating-Cash-Flow Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Novonesis (Novozymes) B's Capex-to-Operating-Cash-Flow falls into.


;
;

Novonesis (Novozymes) B Capex-to-Operating-Cash-Flow Calculation

Novonesis (Novozymes) B's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-2683.279) / 7606.104
=0.35

Novonesis (Novozymes) B's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-411.72) / 793.606
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novonesis (Novozymes) B  (OCSE:NSIS B) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Novonesis (Novozymes) B Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Novonesis (Novozymes) B Business Description

Address
Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

No Headlines